Anti-infectives targeting Gram-negative 'superbugs'
|
New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. The lead candidate novel lipopeptide antibiotic is in advanced preclinical development and has demonstrated superior in vivo efficacy and safety over currently used polymyxin antibiotics.
- Novel lipopeptide antibiotics targeting multidrug-resistant Gram-negative bacteria
- Greater efficacy (particularly against lung infections) and significantly less nephrotoxicity in animal models than currently available antibiotics
- Identified lead candidate that is amenable to scale-up manufacturing and ready for IND-enabling studies
- Potential for administration via intravenous, inhaled or topical routes
- Multidrug resistant MDR gram-negative bacteria
- Infection
- Superbugs'
- Last-line antibiotics
Using their polymyxin drug discovery platform, researchers from the Monash University have identified a series of proprietary polymyxin analogues that are active against Gram-negative ‘superbugs’.
In vivo efficacy and toxicity studies in rodents demonstrate that, compared with polymyxin B and colistin, the lead candidate lipopeptide can be safely dosed at higher levels to achieve significantly improved efficacy against infections, particularly pneumonia, with significantly less nephrotoxicity.
Licensing
01/04/2015 00:00:00
AU 2015240435
CN 201580027296.9
JA 2016-560550
NZ 724798
Others
Monash University has extensive academic and industrial experience in medicinal chemistry, pharmacokinetics/ pharmacodynamics, and in vitro and in vivo evaluations of antibiotics. Monash seeks a partner to complete advanced IND-enabling preclinical assessment of its lead candidate lipopeptide and to undertake clinical development.
2013-061
Australia
